Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
about
Depletion of regulatory T cells leads to an exacerbation of delayed-type hypersensitivity arthritis in C57BL/6 mice that can be counteracted by IL-17 blockade.C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA.Pharmacological Value of Murine Delayed-type Hypersensitivity Arthritis: A Robust Mouse Model of Rheumatoid Arthritis in C57BL/6 Mice.
P2860
Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment with anti-C5aR mAb l ...... ersensitivity arthritis model.
@en
type
label
Treatment with anti-C5aR mAb l ...... ersensitivity arthritis model.
@en
prefLabel
Treatment with anti-C5aR mAb l ...... ersensitivity arthritis model.
@en
P2093
P2860
P1433
P1476
Treatment with anti-C5aR mAb l ...... ersensitivity arthritis model.
@en
P2093
Anneline Nansen
Birgitte Friedrichsen
Bodil-Cecilie Sondergaard
Chih-Chuan Chang
Claus Haase
Lars Hornum
Pernille A Usher
Renhong Tang
Sara M Atkinson
Søren Skov
P2860
P304
P356
10.3109/08916934.2015.1031888
P577
2015-04-27T00:00:00Z